Opthalmic robotic surgery startup ForSight Robotics has completed a $55 million Series A round to advance its ORYOM platform for fully robotic cataract surgery, the company announced Monday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
ForSight's flagship robotic platform is designed to increase accessibility to ophthalmic surgery procedures worldwide and ultimately transform the future of eye surgery.
The Adani Group led the funding round alongside existing investors Eclipse Ventures and Mithril Capital. A number of new investors, including Provenio Capital, Precision Capital, Reiya Ventures, the Ljungstrom family office, and other prominent private investors also joined the round.
ORYOM – which means "daylight" in Hebrew – is designed to automate the complex subtleties of ophthalmic surgery to treat the diseases underlying preventable blindness with an intuitive platform.
"We are pleased to be able to advance our technology with this investment to bring robotics into the world of ophthalmic surgery to help millions of patients who have to wait unnecessarily for procedures while their eyesight deteriorates," says ForSight co-founder and CEO Dr. Daniel Glozman.
